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Background: One barrier to patient adherence with chronic topical glaucoma treatment is an inadequate amount
of medication available between prescription refills. We examined the self-reported prevalence of early exhaustion
of glaucoma eye drops prior to a scheduled refill, and associated risk factors.
Methods: This cross-sectional survey was performed at a University-based clinical practice. Glaucoma patients at
the University of Washington who were experienced with eye drop application and were on a steady regimen of
self-administered glaucoma drops in both eyes took a survey at the time of clinic examination. The main outcome
measure was self-reported early eye drop bottle exhaustion.
Results: 236 patients were eligible and chose to participate. In general, patients included were relatively healthy
(mean 2.3 comorbid medical conditions). Sixty patients (25.4%) reported any problem with early exhaustion of eye
drop bottles, and this was associated with visual acuity ≤ 20/70 in the better eye (P = .049). Twelve patients (5.1%)
reported that they “often” (5–7 times per year), “usually” (8–11 times per year) or “always” ran out of eye drops prior
to a scheduled refill. Patients affected by this higher level (≥5 times yearly) of eye drop bottle exhaustion were
more likely to have poor visual acuity in their worse eye ≤ 20/70 (P = .015) and had significantly lower worse-eye
logMAR (P = .043).
Conclusions: Self-reported early glaucoma bottle exhaustion regularly affected 5% of patients in our population
and 25% reported early exhaustion at least once; the main risk factor was poor vision in at least one eye.
These results may not be generalizable to a broad patient population, or to those inexperienced with eye drop
self-administration. However, this pilot study compels further evaluation and consideration of early eye drop bottle
exhaustion in glaucoma patients.
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BlindnessBackground
Glaucoma, the second leading cause of global blind-
ness [1], is a progressive optic neuropathy with charac-
teristic structural and functional abnormalities. Several
clinical trials have demonstrated that reducing intraoc-
ular pressure (IOP) slows glaucoma progression [2,3],
and proper use of topical ocular antihypertensives im-
proves outcomes. However, numerous reports suggest* Correspondence: pchen@uw.edu
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unless otherwise stated.patients comply with only 70% or less of prescribed
topical treatments [4-7].
Multiple reasons for poor adherence with topical glau-
coma treatment have been implicated including situ-
ational and environmental factors, medication regimen,
patient-related and provider-related factors [8]. Another
barrier to patient compliance is an inadequate amount
of medication available between scheduled prescription
refills, because of difficulty in eye drop administration
with resultant wastage. This is an issue in the United
States (and may be in other developed nations) where
prescription drug benefits ensure access to medicationLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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interval before a refill may be obtained. This may also be
of concern in less developed countries where access to
and availability of medication may be limited. Although
it is not uncommon in the clinic setting to hear patient
complaints about the difficulty of getting refills if eye
drop bottles are prematurely exhausted, no data ex-
ists in the literature regarding the prevalence of this
phenomenon. Therefore we examined the prevalence of
early exhaustion of glaucoma eye drops prior to a sched-
uled refill, and associated risk factors. Recent Centers for
Medicare and Medicaid Services (CMS) changes now
allow refills at 70% of the predicted days of use for pa-
tients with CMS-sponsored prescription drug coverage
in the United States [9], which applies only to roughly
50% of the glaucoma patient population. As of late 2013,
nine states also have passed and several others have
pending legislation to provide coverage for all patients.
The present study was based on patient recall over the
year prior to institution of the CMS changes in a state
without such legislation.
Methods
The Human Subjects Division of the University of
Washington gave approval for this research survey.
Patients were seen in glaucoma subspecialty clinics of
the University of Washington from July 15, 2010 to
December 31, 2010. Patients with a diagnosis of glau-
coma who were prescribed long-term topical glaucoma
therapy in both eyes and who self-administered drops
were eligible for this study. The diagnosis of glaucoma
was determined by standard ophthalmic examination and
ancillary testing by fellowship-trained glaucoma special-
ists (PPC, RCM), and was based upon characteristic optic
nerve appearance regardless of intraocular pressure or
visual field findings. We chose to include only patients
on bilateral treatment because we reasoned that patients
using drops in only one eye on a traditional dosing
regimen would be less likely to run out of medications.
Because the personnel who administered the survey
(CW, KLM) were not able to attend every glaucoma
clinic at the University of Washington, not all eligible
patients were enrolled. However, when the study-
administering personnel were present, all eligible subjects
were asked if they wished to participate in a study of
eye drop use (no mention was made of eye drop bottle
exhaustion). Of the subjects approached to participate in
the study, approximately ten refused to participate.
Patients were required to be on a stable, self-
administered drop regimen with no changes in their
glaucoma therapy during the prior 3 months. After obtain-
ing written informed consent, a short survey was com-
pleted (see Appendix) at the time of their office visit with
the assistance of an in-person interviewer (CW, KLM).The survey was developed by the authors and was based
on clinical experience with patient complaints during
glaucoma clinic visits; it was not further validated. Data
was collected regarding insurance status, self reported in-
cidence of early eye drop bottle exhaustion, specific drops
used, specific drops that were exhausted early, and factors
that the patient considered to be responsible for this oc-
currence. We reviewed the patients’ medical records for
additional data, including visual acuity and most recent
visual field data, including mean deviation (MD), pattern
standard deviation (PSD) and visual field index (VFI). No
automated visual field data existed for some eyes with
poor visual acuity. For bilateral data, we divided eyes into
worse and better eyes, based on visual acuity (visual field
data were used if visual acuities were equal in each eye).
We considered an eye with Snellen visual acuity of 20/70
or worse to have poor visual acuity, corresponding to the
World Health Organization definition of visual impair-
ment [10]. We noted the presence of ophthalmic and
medical comorbidities (arthritis was considered separately),
and number of other prescription medications. Com-
bination drops (e.g. dorzolamide-timolol) were consid-
ered to be one bottle, but two medications. In cases
where glaucoma medications included oral medications
prescribed for intraocular pressure reduction, these were
not considered eyedrops. We did not collect data regard-
ing the brand, fill or bottle type of the medications soli-
cited. Statistical analysis was performed with SPSS 16.0
for Mac (SPSS, Chicago, IL).
Results
A total of 236 patients completed the survey during the
study period. Baseline demographics and characteristics
of the study population are presented in Table 1. Sixty
patients (25.4%) reported early exhaustion of eye drops
at least once in the past year (Table 2). The sole risk fac-
tor significantly associated with this level of early bottle
exhaustion was poor visual acuity (≤20/70) in the better
eye (5/9 vs 55/227; P = .049, Fisher exact test) from any
cause.
Twelve patients (5.1%) reported that they “often” (5–7
times per year), “usually” (8–11 times per year) or
“always” ran out of eye drops before they were able to re-
fill their prescriptions. Risk factors for falling into this
group included poor visual acuity (≤20/70) in the worse
eye from any cause (P = .015), and worse logMAR visual
acuity in the worse eye (P = .043) (Table 3). Reasons for
poor visual acuity (≤20/70) for either eye are listed in
Table 4. No other significant risk factors were found,
specifically including systemic medical problems such
as arthritis (N = 47), diabetes mellitus (N = 32), history
of cerebrovascular accident (N = 6), Parkinson’s disease
(N = 5), essential tremor (N= 7), and any peripheral neur-
opathy (N = 6) (P > .455; data not shown). No association
Table 1 Demographics/characteristics of the study
population (N = 236)





Better eye MD: −4.2 ± 5.7 dB
PSD: 4.2 ± 3.4 dB
VFI: 90 ± 16%
Worse eye MD: −8.5 ± 8.1 dB
PSD: 6.5 ± 4.2 dB
VFI: 77 ± 25%
Duration of treatment 7.9 ± 5.9 yrs
No prescription insurance 23 (9.7%)
Number of eye drop bottles 2.1 ± 0.8
Number of comorbid conditions* 2.3 ± 1.8
Number of prescription medications* 3.3 ± 3.2
Mean ± SD; MD =mean deviation; PSD = pattern standard deviation; VFI = visual
field index.
*Other than glaucoma.
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type of insurance (Medicaid vs. Medicare vs. private), and
early bottle exhaustion (data not shown).
Our survey included questions regarding possible rea-
sons that the patient felt contributed to early bottle
exhaustion, and 88 total responses were given (some pa-
tients listed more than one reason) (Table 5). Of these,
the most frequently cited were “insufficient amount in
bottle,” “more than one drop comes out,” “can’t hold
bottle steady,” “can’t see tip of bottle” and “size of the
drops is too large.” Some noted problems with the bot-
tle, specifically that they are not clear, making it difficult
to see when the amount of medication is running low.
Only 4.5% reported the problem was due to missing the
eye with the eye drop.
Among medications being used by at least 10% of sub-
jects, the lowest rate of early bottle exhaustion was seenTable 2 Frequency of reported inadequate eyedrop
bottle volume
Frequency N (%)
Rarely (1-2x/yr) 29 (12.3)
Sometimes (3-4x/yr) 19 (8.1)
Often (5-7x/yr) 1 (0.4)
Usually (8-11x/yr) 4 (1.7)
Always 7 (3.0)
Total 60 (25.4)among subjects using brimonidine (4/74, 5.4%), and the
highest rate was seen with latanoprost (13/80, 16.3%)
(Table 6).
Discussion
Poor adherence with treatment has been reported as a
risk factor for progression to blindness in glaucoma
patients [11-13]. This study evaluated the self-reported
prevalence of early glaucoma eye drop bottle exhaustion
and found 25% of patients reported their bottles did not
last until the next allowed refill at least once yearly,
and for 5% of patients this occurred on a regular
basis (at least 5 times per year). The actual number of
patients affected may be even greater, as self-reported
non-anonymous studies may underestimate the preva-
lence of a given problem, due to response bias [14]. Re-
cent CMS changes (at the United States national level)
and some state Medicaid changes now allow refills of
prescription drugs at 70% of the predicted days of use
for patients with prescription drug coverage [9], but
this only applies to patients who are Medicare benefi-
ciaries who have enrolled in Part D; in 2011, approximately
13.5 million persons (~28% of those enrolled in Medicare)
were not covered by Part D plans [15]. In addition, non-
Medicare prescription drug insurance plans are not re-
quired to follow the same CMS rules. As such, although
there are many potential reasons patients who exhaust
their medications earlier than a scheduled refill may not
collect new medications, insurance restrictions have been a
significant barrier in the United States.
We found an association between poor visual acuity in
the worse eye (from any etiology, though in our study
about one quarter of worse-affected eyes were damaged
by glaucoma) and higher levels of early bottle exhaus-
tion. One possible explanation for this finding may be
“increased” adherence with therapy (perhaps better termed
over-adherence) as compared to patients with less severe
disease. Some investigators have suggested that fear of
blindness is a motivator for adherence [16]. Similarly, pa-
tients considered glaucoma suspects are less adherent with
therapy than patients diagnosed with glaucoma [17,18].
However if such over-adherence leads to early bottle ex-
haustion, this may only worsen advanced disease. Thus the
individuals most affected by early bottle exhaustion are
those who need their glaucoma medication the most –
those who have limited sight.
In addition, administration of eye drops requires dex-
terity and hand-eye coordination; good visual acuity and
the ability to aim are necessarily interrelated [19]. In-
deed, videotaping of glaucoma patients has shown they
used an average of 1.4 - 1.8 drops when trying to instill a
single eye drop [20,21], which would result in a need to re-
fill medications earlier than expected. A previous study
evaluating disease severity and eye-drop administration
Table 3 Selected risk factors for early eye drop bottle exhaustion among patients who report often, usually, or always
running out of drops early (at least 5 times yearly)
Factor Yes, runs out No, does not P
Age (yrs) 71.7 ± 11.3 67.1 ± 14.2 .271*
Years of glaucoma drop use 10.9 ± 7.6 7.8 ± 5.8 .070*
Poor visual acuity (≤20/70)
Better eye 2/12 (16.7%) 7/224 (3.1%) .070†
Worse eye 6/46 (13.0%) 6/190 (3.2%) .015†
logMAR visual acuity
Better eye .505 ± 1.03 .087 ± .199 .188*
Worse eye .881 ± 1.06 .397 ± .787 .043*
Visual field
Mean deviation (dB), better eye −6.7 ± 7.6 −4.1 ± 5.6 .131*
Visual Field Index, better eye 81 ± 21 90 ± 16 .198*
Mean deviation, worse eye −12.0 ± 13.3 −8.4 ± 7.8 .387*
Visual Field Index, worse eye 63 ± 40 78 ± 23 .228*
Number of comorbid conditions (mean ± SD) 2.8 ± 2.0 2.3 ± 1.8 .274*
Number of prescription medications (not including eye drops) 5.3 ± 5.4 3.2 ± 3.0 .228*
Number of bottles 2.1 ± 1.2 2.1 ± 0.8 .962†
Number of eye drops/day 6.2 ± 4.5 6.6 ± 3.8 .235†
*t-test, 2-tail; †Chi square or Fisher Exact test, 2-tail.
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was a significant association between worse instillation
technique and the eye with greater visual field loss [22].
Visual field data was not associated with early bottle ex-
haustion in our patient population, though this is probably
related to the lack of automated visual field testing in eyes
with very poor visual acuity. Systemic conditions such as
cerebrovascular accident, tremor, Parkinson’s disease,
and peripheral neuropathy were poorly represented inTable 4 Reasons for reduced visual acuity (≤20/70)




Glaucoma (any type) 1 (11%) 11 (24%)
Retinal vein occlusion 0 6 (13%)
Age-related macular degeneration 2 (22%) 5 (11%)
Myopic retinal degeneration 2 (22%) 5 (11%)
Cataract 0 3 (7%)
Amblyopia 1 (11%) 3 (7%)
Retinal detachment 0 3 (7%)
Dry eye disease 1 (11%) 2 (4%)
Posterior uveitis 1 (11%) 2 (4%)
Diabetic retinopathy 0 1 (2%)
Other* 1 (11%) 4 (9%)
*Includes Non-arteritic ischemic optic neuropathy, retinopathy of prematurity,
irregular astigmatism after penetrating keratoplasty, macular hole.our study population, possibly because we excluded pa-
tients who did not administer their own drops, and pa-
tients severely afflicted by the aforementioned diseases
probably must rely on caretakers to administer their eye-
drop medications.
Although many of the factors cited by our subjects as
reasons for early bottle exhaustion are likely amenable
only to personalized instruction or use of an eyedrop
dispensing aid, some of them might be amenable to
changes in eye drop bottle manufacture: such as colored
bottle tips that would allow patients to see the tip of the
bottle more easily, clear or translucent bottles so patients
could see when they are running low on medication, andTable 5 Patient questionnaire responses regarding
factors contributing to early bottle exhaustion
Patient-reported reason for early bottle exhaustion N (%)
More than one drop comes out 27 (30.6)
Insufficient amount in bottle 16 (18.1)
Drop size too large/inconsistent 16 (18.1)
Can’t see tip of bottle 10 (11.4)
Can’t hold bottle steady 8 (9.1)
Misses eye 4 (4.5)
Not sure why 3 (3.4)
Poor vision 2 (2.3)
Can’t see if bottle empty 2 (2.3)
Table 6 Number of eyedrops used, exhausted and
percentage of drop exhaustion among those with any
early eyedrop bottle exhaustion, and those with frequent
(≥5 times per year) early eyedrop bottle exhaustion
Medication N patients
using drop




Timolol/Dorzolamide 89 7 (7.9) 4 (4.5)
Latanoprost 80 13 (16.3) 3 (3.8)
Brimonidine 74 4 (5.4) 1 (1.3)
Timolol 64 10 (14.5) 3 (4.7)
Travoprost 66 10 (15.2) 3 (4.5)
Bimatoprost 41 6 (14.6) 2 (4.9)
Dorzolamide 18 0 0
Pilocarpine 17 2 (11.7) 0
Brinzolamide 16 2 (12.5) 0
Timolol/Brimonidine 5 1 (20.0) 0
Apraclonidine 5 1 (20.0) 0
Betaxolol 5 2 (40.0) 0
Carteolol 5 2 (40.0) 0
Levobunolol 3 0 0
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tion (or greater adoption of existing instillation aids)
among those at risk for early bottle exhaustion. Although
the reasons we listed on the survey might appear to direct
our subjects’ responses, in fact 43% of responses were listed
under “other.” Clearly, given the difficulty in eye drop ad-
ministration, the development of an alternative eye drop
delivery system would be welcome.
No association was found between medical insurance
status nor prescription drug insurance status, and early
eye drop bottle exhaustion, although only a small pro-
portion of our study population was uninsured. While
we did not collect data on out-of-pocket drug cost or so-
cioeconomic data for our subjects, the lack of associ-
ation seen with insurance status or type implies that
socioeconomic status may not influence the rate of early
bottle exhaustion, which is consistent with other studies
that have looked at other sociodemographics such as
educational level [6,13,23,24]. A reasonable conclusion,
based on our findings and those of other authors, would
be that problems with eye drop administration are present
across socioeconomic stations and are not related to drug
cost or insurance status.
That patients with glaucoma may have poor adherence
to topical treatment is not a novel finding. The usual im-
plication is that insufficient medicine is taken despite
adequate supply [23-25], although some authors have
found that 7-13% of patients overused topical glaucoma
drops on a regular basis, 6–7 days per month [5,26]. Our
study suggests that providers must also be cognizant ofearly bottle exhaustion when managing glaucoma patients.
Patients with poor vision may have particular difficulty
with this issue; unfortunately, these may be the patients
that need well-controlled IOP the most. However, treat-
ment should be individualized, since a multitude of
factors may interfere with compliance [8]. Medication
insurers and pharmacy staff should acknowledge that
some patients will have early bottle exhaustion, and
should make allowances for early eye drop bottle refills, as
is currently permitted under Medicare Part D. Although
patients desire personalized instruction on eyedrop ad-
ministration [27], and while it makes sense that improved
training of patients in eyedrop self-administration might
also reduce the number of patients that have difficulty
with this basic aspect of glaucoma treatment, there is cur-
rently no evidence in the literature that supports such a
contention [28].
Several limitations of our study must be acknowl-
edged. Our data collection relied solely on patient recall,
and was not validated with pharmacy refill data, with
observation of eye drop instillation practices or with pa-
tient involvement. We studied a relatively small popula-
tion at a single academic center, and our results may not
be generalizable to other populations. Given the small
number of patients with higher levels of early bottle
exhaustion, our findings on risk factors for early bottle
exhaustion should be interpreted with caution. Re-
sponse bias may have led some patients to minimize or
maximize the extent of their difficulties, although we
attempted to word our survey carefully in an attempt to
avoid such bias. Further investigation of this subject
might focus on a larger sample size, prospective measure-
ment via pharmacy refill data, use of eye drop application
aids among patients who report difficulty with early eye
drop bottle exhaustion and length of time patients must
go without medication, as well as coping mechanisms
that patients employ to “stretch out” their medication eye
drop supply.
Conclusions
Self-reported early glaucoma bottle exhaustion regularly
affected 5% of patients in our glaucoma clinic popula-
tion, and 25% reported early exhaustion at least once
yearly; the main risk factor was poor vision (Snellen acu-
ity of 20/70 or worse) in at least one eye. Our survey
was only conducted on experienced eyedrop users who
self-adminstered their eyedrops bilaterally, and therefore
these results may not be generalizable to a broad patient
population with patients suffering from numerous med-
ical issues, or with those inexperienced with eye drop
self-administration. However, this pilot study compels
further data collection and research, and consideration
of early eye drop bottle exhaustion in at-risk glaucoma
patients in the clinic.
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1. How many different bottles of glaucoma eye drops do
you use?
1____ 2____ 3____ 4 or more_____
2. Do you have any kind of insurance plan that helps to
pay for your glaucoma eye drops?
a. Yes____
If yes, is this Medicare Part D? Yes____ No____
If yes, name of insurance (if known)__________________
b. No____
3. How often do you think you run out of eye drops before
the end of the month, or before your insurance company
will allow you to re-order your drops?
a. Never_____
b. Rarely - not more than once or twice per year_____
c. Sometimes - 3 to 4 times per year_____
d. Often - 5 to 7 times per year_____
e. Usually - 8 to 11 times per year_____
f. Always_____
4. Which of your medications usually runs out early?
Name of medication(s)_____________________________
It varies, cannot say____
5. Why do you think you usually run out of drops earlier
than you are supposed to? Check all that apply.
I miss my eye because I can’t see the bottle tip
well_____
I miss my eye because I can’t hold the bottle
steady_____
More than one drop comes out______
The size of the drops is too large______
Other reason (please list)____________________________
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